09:55 AM EST - Aurinia Pharmaceuticals Inc. : Highlighted additional findings from its global Phase IIb AURA study of voclosporin in the treatment of lupus nephritis. The abstract was presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington, D.C. during the Late-Breaking News session on November 15. Aurinia Pharmaceuticals Inc.
shares T.AUP are trading up $0.29 at $5.45.
